Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.
about
p63 maintains keratinocyte proliferative capacity through regulation of Skp2-p130 levels.NCI's provocative questions on cancer: some answers to ignite discussion.Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatmentMutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Circ-ZEB1.33 promotes the proliferation of human HCC by sponging miR-200a-3p and upregulating CDK6
P2860
Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Racing to block tumorigenesis ...... wins with synthetic lethality.
@en
Racing to block tumorigenesis ...... wins with synthetic lethality.
@nl
type
label
Racing to block tumorigenesis ...... wins with synthetic lethality.
@en
Racing to block tumorigenesis ...... wins with synthetic lethality.
@nl
prefLabel
Racing to block tumorigenesis ...... wins with synthetic lethality.
@en
Racing to block tumorigenesis ...... wins with synthetic lethality.
@nl
P2860
P356
P1433
P1476
Racing to block tumorigenesis ...... wins with synthetic lethality.
@en
P2093
Frederick Bauzon
P2860
P304
P356
10.4161/CC.9.11.11726
P577
2010-06-01T00:00:00Z